Allogene Therapeutics (ALLO) Net Margin (2021 - 2026)
Allogene Therapeutics (ALLO) posted Net Margin of 353104.55% for Q1 2024, down 1.8% sequentially from 346876.19% in Q4 2023, and down 1966121.0% YoY from N/an in Q2 2023.
Allogene Therapeutics (ALLO) Net Margin (2021 - 2026) Analysis & Trends
Allogene Therapeutics has reported Net Margin for 4 years, with the latest figure at 353104.55% in Q1 2024.
- Quarterly Net Margin fell 1966121.0% year-over-year to 353104.55% in Q1 2024, while the trailing twelve-month figure through Dec 2024 was 1844954.55% (down 144767665.0% YoY) and the FY2024 annual result came in at 1170863.64%, down 82637416.0% from the prior year.
- Net Margin slipped to 353104.55% in Q1 2024 per ALLO's latest filing, from 346876.19% in the prior quarter.
- Over five years, Net Margin peaked at 4.05% in Q4 2021 and troughed at 833066.67% in Q3 2022.
- A 4-year average of 324906.08% and a median of 333947.73% in 2021 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2023: Net Margin plunged 50573401 bps in 2022, then surged 41701212 bps in 2023.
- Over 4 years, Net Margin stood at 4.05% in 2021, then plunged by 9541221 bps to 386684.62% in 2022, then grew by 10 bps to 346876.19% in 2023, then slipped by 2 bps to 353104.55% in 2024.
- According to Business Quant data, Net Margin over the past three periods registered 353104.55%, 346876.19%, and 416054.55% for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | -3,053.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,053.21% |
| Mar 31, 2024 | -353,104.55% |
| Dec 31, 2023 | -346,876.19% |
| Sep 30, 2023 | -416,054.55% |
| Jun 30, 2023 | -513,659.09% |
| Mar 31, 2023 | -333,443.33% |
| Dec 31, 2022 | -386,684.62% |
| Sep 30, 2022 | -833,066.67% |
| Jun 30, 2022 | -170,493.75% |
| Mar 31, 2022 | -209,030.77% |
| Dec 31, 2021 | 4.05% |
| Sep 30, 2021 | -327,332.65% |
| Jun 30, 2021 | -333,947.73% |
| Mar 31, 2021 | -89.19% |